As a commercial production, JUQ-063 was released in several formats and versions:
If you have more specific information about "JUQ-063," such as the intended use of the paper or the manufacturer, I could potentially provide more tailored information. JUQ-063
| Parameter | Details | |-----------|----------| | | Human cannabinoid receptors CB₁ and CB₂ | | Binding affinity (Kᵢ) | CB₁ ≈ 2 nM, CB₂ ≈ 6 nM (reported in vitro radioligand assays) | | Functional activity | Full agonist at both receptors (high intrinsic efficacy) | | Metabolism | Predominantly oxidative dealkylation, aromatic hydroxylation, and amide hydrolysis mediated by CYP3A4 and CYP2C19. Major metabolites are glucuronide conjugates excreted in urine. | | Pharmacokinetics (animal data) | Rapid absorption after oral administration, peak plasma concentrations within 30–45 min, half‑life ≈ 2–3 h (parent) with longer‑lasting active metabolites. | | Physiological effects | Typical cannabinoid profile: analgesia, hypothermia, catalepsy, reduced locomotor activity, and modulation of appetite. At higher doses, pronounced psychoactive effects, tachycardia, and potential anxiogenic reactions have been reported. | As a commercial production, JUQ-063 was released in
One hypothesis, put forward by the Institute for Quantum Materials in Zurich, suggests that JUQ‑063 designates a specific topological qubit architecture. Topological qubits exploit non‑abelian anyons—quasiparticles whose exchange operations (braiding) form the basis of fault‑tolerant quantum computation. The “JUQ” could be an acronym for , a research group that, in 2035, reported a prototype where superconducting nanowires intersected with semiconducting quantum dots to host Majorana zero modes. The “063” could then refer to a particular braiding sequence (six operations, three of which are nontrivial) that yields a universal gate set. | | Pharmacokinetics (animal data) | Rapid absorption
A second, more mathematically inclined reading treats JUQ‑063 as a shorthand for a family of quantum error‑correcting codes. In the nomenclature of stabilizer codes, a string like “[[n,k,d]]” describes the number of physical qubits ( n ), logical qubits ( k ), and code distance ( d ). The “JUQ” prefix could denote a ust‑in‑time U niversal Q uasi‑code, a hybrid that blends features of surface codes (high threshold, locality) and concatenated codes (flexibility). The number “063” might indicate the code’s parameters (e.g., n = 6, k = 3, d = 3 ), a compact configuration that offers a surprisingly high logical fidelity for a modest qubit overhead.
| Aspect | Findings | |--------|----------| | | LD₅₀ in mice ≈ 120 mg kg⁻¹ (oral). Signs of toxicity include sedation, ataxia, and, in some cases, seizures at supra‑therapeutic doses. | | Chronic exposure | Limited data; animal studies suggest tolerance development and modest receptor down‑regulation after repeated dosing. | | Potential adverse effects | ‑ Cardiovascular: tachycardia, hypertension ‑ Neurological: anxiety, paranoia, occasional psychosis‑like symptoms ‑ Gastrointestinal: nausea, vomiting ‑ Renal/hepatic: elevation of liver enzymes in some case reports | | Drug‑drug interactions | Because metabolism relies heavily on CYP3A4, concurrent use of strong inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin) can markedly alter plasma concentrations. |